Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

AQB vs ACAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: AQB 0 – 6 ACAD Matrix Metrics: AQB 0 – 10 ACAD

As of Nov 17, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over AquaBounty Technologies, Inc. (AQB) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQB carries a Unified Composite Score of 44.6/100 (HOLD) at $0.82 (N/M Forward P/E, 0.0% operating margin), whereas ACAD carries 47.9/100 (HOLD) at $18.32 (16.9x Forward P/E, 10.2% operating margin).

  • Technical & Structure Timing Caution: AQB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQB vs ACAD
AQB NASDAQ
AquaBounty Technologies, Inc.
Fishing, Hunting And Trapping
$0.82
+2.01% 1D
Market Cap $9.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.93β · 117% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 33.0 Fund 49.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 37
RSI-14: 37.5 · SMA20: $1.04 · SMA50: $1.03
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$18.32
-1.87% 1D
Market Cap $3.2B
TTM Revenue $1.20B
Forward P/E 16.9x
Beta / 30D Vol 0.16β · 90% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 48.0 Fund 57.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.0%), weak momentum, RSI 40
RSI-14: 39.8 · SMA20: $19.69 · SMA50: $21.41

6-Pillar Scorecard Institutional Category Breakdown (AQB 0 – 6 ACAD)

Columns: Metric · AQB · ACAD
1. Valuation Multiples ACAD
Forward P/E N/M 16.9x
Trailing P/E N/M 8.8x
PEG Ratio N/M N/M
EV / Revenue N/M 2.5x
2. Growth & Scale ACAD
Revenue Growth (YoY) -93.5% +22.8%
Earnings Growth (YoY) +0.0% -26.2%
TTM Revenue (USD) N/A $1.20B
Market Cap $9.7M $3.2B
3. Profitability & Quality ACAD
Gross Margin N/A 63.9%
Operating Margin 0.0% 10.2%
Net Profit Margin 0.0% 30.1%
Return on Equity (ROE) -68.9% 31.4%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) -$7.2M $181M
Cash Flow Margin N/A 15.0%
Net Cash / Leverage $0.19 Book/Sh · -68.9% ROE $251M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACAD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 66.1% (9th %ile)
Put/Call OI Skew N/A 6.67x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity N/A 53.7% of Rev ($646M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Farm Products Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQB (0) vs ACAD (10)
Institutional Metric AQB ACAD Criterion Row Edge
Market Capitalization
Scale
$9.7M $3.2B Larger Scale ACAD
Trailing P/E Ratio
Valuation
N/M 8.8x Lower Multiple ACAD
Forward P/E Ratio
Valuation
N/M 16.9x Lower Multiple ACAD
Revenue Growth (YoY)
Growth
-93.5% +22.8% Higher Growth ACAD
Operating Margin (TTM)
Profitability
0.0% 10.2% Higher Margin ACAD
Net Profit Margin
Profitability
0.0% 30.1% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
-68.9% 31.4% Higher ROE ACAD
52-Week Range Position
Momentum
11% ($1–$2) 16% ($16–$31) Stronger Trend ACAD
Beta / 30D Volatility
Risk Regime
0.93β · 117% Vol 0.16β · 90% Vol Lower Realized Risk ACAD
Unified Institutional Score
Composite Signal
44.6 / 100 (HOLD) 47.9 / 100 (HOLD) Higher Composite ACAD
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 63.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.2M ($0.19 Book/Sh · -68.9% ROE) $181M ($251M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACAD +13.9 pp
AQB: -21.37% · ACAD: -7.47%
3M Horizon AQB +0.85 pp
AQB: -38.51% · ACAD: -39.36%
6M Horizon ACAD +10.82 pp
AQB: -21.37% · ACAD: -10.55%
1Y Horizon AQB +0.16 pp
AQB: -23.57% · ACAD: -23.73%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AQB Revenue ACAD Revenue AQB Op. Margin ACAD Op. Margin Margin Leader
FY2018 $0M $220M -12264.6% -110.6% ACAD
FY2019 $0M $340M -7057.3% -72.7% ACAD
FY2020 $0M $440M -12727.1% -64.9% ACAD
FY2021 $0M $480M -1883.0% -35.2% ACAD
FY2022 $0M $520M -711.6% -43.2% ACAD
FY2023 $0M $730M -552.9% -10.1% ACAD
FY2024 N/A $960M N/A 24.1% ACAD
FY2025 N/A $1.07B N/A 9.8% ACAD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQB BREAKDOWN
69d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AQB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
59d in phase · OBV DISTRIBUTION
Current IV 66.1%
IV Percentile 9th %ile
Put/Call OI Skew 6.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $18.67 · IV 48.0%

ACAD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,867)

Compare $1,867 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.0% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $17 / $16 Bull Put Spread

Sell 3x $17P · Buy 3x $16P · 32d

Net Entry $75 Credit
Max Credit / Yield +$75 (+33.3% RoM)
Max Risk / Buffer -10.3% Cushion ($225 Mgn)
5d Edge & Liquidity 76% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $20 / $17 Bear Put Spread

Buy 1x $20P · Sell 1x $17P · 32d

Net Entry $85 Debit
T+5d @ -5% Drop +$54 (+64%)
Max Risk / Buffer $85 Capped
5d Edge & Liquidity 1.4x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQB Moat Profile Cyclical / Execution-Driven Positioning
Farm Products Operator
Competes within the Farm Products value chain with $9.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published

Investor FAQ AQB vs ACAD Key Questions & Quantitative Answers

As of Nov 17, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over AquaBounty Technologies, Inc. (AQB) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQB carries a Unified Composite Score of 44.6/100 (HOLD) at $0.82 (N/M Forward P/E, 0.0% operating margin), whereas ACAD carries 47.9/100 (HOLD) at $18.32 (16.9x Forward P/E, 10.2% operating margin). Technical & Structure Timing Caution: AQB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACAD leads the Growth & Scale pillar: AQB posts -93.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AQB cumulative revenue shifted N/A while ACAD shifted +386.4%. In operating R&D and SG&A reinvestment, AQB deploys N/A (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.

ACAD screens cheaper on headline valuation multiples. AQB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ACAD trades at 16.9x Forward P/E, 8.8x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQB (-68.9% ROE) versus ACAD (31.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AQB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.93β · 117% Vol realized risk). By comparison, ACAD carries 66.1% implied volatility (9th %ile, Compressed (<25th %ile)), a 6.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.16β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.